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Introduction
H
epatitis  B  Virus  (HBV)  is  a  well-known 
agent of acute and chronic liver disease, and 
persistent HBV infection is closely associated with the 
development of cirrhosis and hepatocellular carcinoma. 
Around 400 million people worldwide carry the virus, 
and more than 250 million reside in Asia (1). Based 
on the divergence of nucleotide sequences exceeding 
8% in the entire genome or 4% in the S gene, HBV 
has  been  classified  into  eight  genotypes  designated 
by capital letters A through H (2). These genotypes 
show  variation  in  their  geographic  distribution 
(3).  Furthermore,  some  studies  have  explained  the 
correlation  between  these  genotypes,  the  clinical 
course of the disease, and responses to treatment (4).
In  the  natural  course  of  chronic  HBV  infection, 
the loss of HBeAg expression and the appearance of 
antibodies  directed  against  it  (Anti-HBe)  are  usually 
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Background and Aims: To investigate the prevalence and pattern of PC and BCP mutations and their clinical significance 
in patients with genotype D chronic hepatitis B infection in the Fars province of southern Iran.
Materials and Methods: From January 2007 to March 2008, we evaluated 44 patients with chronic hepatitis B infection 
who were referred to our hepatology clinics affiliated with the Shiraz University of Medical Science. All Patients were 
HBeAg Negative and HBeAb positive. Basal core promoter and precore mutations in these patients were evaluated with 
clinical phenotype and laboratory tests. 
Results: The mean age of the patients was 37.21 ± 10.54 years. Twenty-seven patients (61.4%) had no mutations, whereas 
17 patients (38.6%) had mutations in the precore or basal core promoter regions or both. The mean serum ALT level in 
mutation-free patients was 59.74 ± 55.86 IUL, whereas patients with PC and BCP mutations had a mean serum ALT level 
of 71.35 ± 59.49 IUL. The mean serum AST level in patients with mutations was higher than for patients without mutations 
(59.53 ± 41.35 IUL vs. 40.65 ± 25.21 IUL, respectively). There was no statistically significant difference between the mutation 
and mutation-free groups in terms of age, sex, and liver enzyme levels (P > 0.05). Fourteen of the 44 patients (31.8%) had 
mutations in the precore region (G 1896A). 17 patients (38.6%) had mutations in basal core promoter region. 
Conclusion: This study revealed a high prevalence of precore and basal core promoter mutations in southern Iran. 
Although no statistically significant difference was noted in liver enzymes, patients with mutations had higher liver 
enzymes in comparison with mutation-free patients. 
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accompanied by a cessation of viral replication. However 
such a serological profile may also be seen in individuals 
who  harbor  precore  (PC)  and  basal  core  promoter 
(BCP) mutants in which replicative infection continues. 
Mutations in the BCP of the HBV (T1762/A1764) 
and PC region (A1896) were previously reported to be 
linked with HBe antigen seroconversion (SC) and viral 
replication. They were often found in the patients with 
advanced  liver  disease  and  hepatocellular  carcinoma. 
Considering  the  important  effect  of  PC  and  BCP 
mutations on the course of the disease and especially 
on the efficacy of different types of treatment and the 
similarity of the serological profile to wild-type inactive 
HBV (negative HBe Ag, positive Anti-HBe Ab), accurate 
and reliable data about the prevalence and types of PC 
and BCP mutations and their impacts on the course of 
chronic hepatitis in Iranian patients are greatly needed. 
The present study aimed to determine the prevalence 
and pattern of PC and BCP mutations and their clinical 
significance in patients with genotype D chronic HBV 
infection in the Fars province of southern Iran.
Materials and Methods
Patients
From January 2007 to March 2008, 44 HBsAg-
positive patients were referred to our outpatient liver 
clinics at the Shiraz University of Medical Science 
in the Fars province of Iran. All of the patients had 
chronic hepatitis B infection (defined as more than 
6 months of infection) and all were HBeAg negative 
and  HBeAb  positive.  None  of  the  patients  had 
associated infections (such as HCV, HDV, and HIV) 
or concomitant liver diseases including autoimmune 
hepatitis, Wilson›s disease, primary biliary cirrhosis, 
alcoholic liver disease, and nonalcoholic fatty liver 
disease. None of the patients had received Lamivudin 
or interferon as a treatment for hepatitis B.
Laboratory tests
During  the  initial  visit,  measurements  of  serum 
aspartate  aminotransferase  (AST)  and  alanine 
aminotransferase  (ALT)  levels  were  obtained  from 
all 44 patients. HBeAg and anti-HBe were measured 
with  commercially  available  kits  (AxSYM,Abbott 
Laboratories, North Chicago, IL, USA) with a micro-
ELISA method. HBV DNA was extracted from 200 μl 
of serum using a QIAamp DNA Blood Mini Kit (Qiagen 
GmbH, Germany) and amplified by an in-house PCR 
assay with a detection limit of 1000 geq/ml. 
Determination of PC and BCP mutations
The  PC  and  BCP  mutations  were  determined 
using  a  line  probe  assay  (INN0-LIPA  HBV  PC), 
developed by INNOGENETICS (Ghent, Belgium). 
The PC and BCP regions were amplified by nested 
PCR  with  biotinylated  primers  provided  by  the 
manufacturer. Five microliters of the first-and second-
round PCR products were analyzed by electrophoresis 
in a 2% agarose gel stained with ethidium bromide 
and  visualized  with  an  ultraviolet  transilluminator. 
For samples with detectable HBV DNA after nested 
PCR,  10  microliters  of  amplified  products  were 
applied  to  the  strips,  which  were  precoated  with 
specific  oligonucleotide  probes  for  wild-type  HBV 
(A1762/G1764) and frequently occurring mutations 
in the core-promoter region (A1762/A1764, A1762/
T1764 and T1762/A1764), and probes for mutant 
PC codon 28 (TAG). Following reverse hybridization 
of the bitinylated PCR fragments in the LiPA strips, 
streptavidin-alkaline phosphatase incubation and color 
development were used to identify reactive probes. 
LiPA
Equal volumes (10 microliters) of the biotinylated 
PCR fragment and the denaturation solution were 
mixed in test troughs for 5 min, after which 2 ml 
of the prewarmed hybridization solution was added, 
followed by the addition of one strip per trough. 
Hybridization occurred for 1 hr at 50±5º C in a 
closed water bath with back-and-forth shaking. The 
strips were rinsed twice with 2 ml of rinse solution. 
Strips were incubated on a rotating platform with 
alkaline phosphatase- labeled streptavidin conjugate 
for 30 min at 20 to 25 ºC. Strips were then washed 
twice with rinse solution, and color development was 
initiated  with  the  addition  of  5-bromo-4-coro-3-
indolyphosphate (BCIP) and stopped by aspirating 
the  substrate  buffer  and  adding  distilled  water. 
Immediately after dying, the strips were interpreted. 
Ethics and consent
This study was approved by the Ethics Committee 
of the Shiraz University of Medical Science, where 
the work was undertaken. The study also conforms 
to the provisions of the Declaration of Helsinki (as 
revised in Edinburgh 2000).
Statistical analysis
Results are expressed as mean ± SD. Data were 
analyzed by independent sample t-tests, two-tailed 
Fisher's exact and Chi Square tests when appropriate 
using  SPSS  software  (version  12.0,  SPSS  Japan 
Inc.,  Tokyo).  P  values  of < 0.05  were  considered 
statistically significant.
Results
All of the patients had genotype D HBV infection. Hepat Mon. 2010; 10(4): 294-297
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PC A1896 mutation had simultaneous mutations at 
the BCP region. The other considerable point in our 
study was that all the patients had mutation from 
G to A at nucleotide 1896 (G1896A), and no other 
forms of mutations were observed in the PC region. 
This may be due to geographical differences and, 
secondly, to the age of our patients. The patients in 
other studies have generally been older with more 
chronic diseases; providing enough time for the PC 
region to replicate more and produce several patterns 
of PC mutations (12).
BCP mutation was detected in 17 (38.6%) of our 
patients. There were 3 patterns of BCP mutations 
in our patients. The most common form of BCP 
mutation  was  T1762/A1764  (25%),  followed  by 
A1762/A1764  and T1762/G1764,  both  with  the 
same frequency (n = 3). Although previous studies 
have reported a higher prevalence of T1762/A1764 
mutations  in  HBV  genotype  C  patients  (13),  this 
pattern  of  mutation  was  more  prevalent  in  our 
patients, all of whom had HBV genotype D infection. 
As  previously  mentioned  in  the  methods  section, 
we categorized our patients into 5 classes. Patients 
in  Class  2,  who  had  T1762/A1764  mutations, 
were  older  than  the  patients  in  other  classes  and 
had mildly elevated serum levels of AST and ALT. 
This is compatible with other studies on older HBV 
patients (14). However, Patients in class 3 (who had 
PC mutations at T1762/A1764) were the youngest 
among the 5 groups. It should be noted that due to 
the small number of patients in each class, a statistical 
comparison between classes was not possible. The 
other BCP mutations in our patients occurred in the 
A1762/A1764 region (Class 1) and at T1762/G1764 
(Class  4).  Patients  with  A1762/A1764  mutations 
(Class 1) had the highest serum levels of AST and 
ALT. 
The clinical and virologic significance of PC and 
BCP mutations are not fully understood. Some studies 
have shown an association between these mutations 
and  more  severe  liver  damage  and  hepatocellular 
carcinoma  (5). In the present study there were no 
significant differences by age, sex, and level of liver 
enzymes between patients with mutations and those 
without mutations. This finding may stem from the 
small number of patients in our study. Further studies 
with larger sample sizes are necessary to elucidate the 
exact role of these mutations in the clinical course of 
HBV infection. 
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